Novanta Inc. — FY2022 Form 10-K
Reporting period: Fiscal year ended December 31, 2022. Although the request references 2022 Q4, the supplied filing reports annual results; it does not provide a clear standalone fourth-quarter financial summary. Amounts are in U.S. dollars unless noted.
Business context
Novanta supplies photonics, vision and precision-motion components and subsystems to medical and advanced industrial OEMs. FY2022 revenue was approximately 49% medical and 51% advanced industrial. The company has three reportable segments: Photonics, Vision and Precision Motion. In August 2022, it acquired Czech medical-consumables manufacturer MPH for approximately $22.4 million, net of cash acquired.
Key financial results
| Metric | FY2022 | FY2021 |
|---|---|---|
| Revenue | $860.9 million | $706.8 million |
| Gross profit / margin | $378.5 million / 44.0% | $300.3 million / 42.5% |
| Operating income / margin | $103.1 million / 12.0% | $64.1 million / 9.1% |
| Net income | $74.1 million | $50.3 million |
| Diluted EPS | $2.06 | $1.41 |
| Cash from operating activities | $90.8 million | $94.6 million |
| Cash and cash equivalents at year-end | $100.1 million | $117.4 million |
- Revenue increased 21.8%; management attributed growth to acquisitions and higher demand. Acquisitions contributed $93.3 million; foreign exchange adversely affected revenue by $36.9 million, as described in the filing.
- Segment revenue and operating income: Photonics $274.7 million and $63.8 million; Vision $278.0 million and $28.2 million; Precision Motion $308.2 million and $60.3 million.
- Gross margin improvement reflected higher segment margins, with factory productivity, efficiency and utilization gains partly offset by supply-chain disruption and inflation. Operating income rose 60.9%, while net income increased 47.1%.
- Net interest expense rose to $15.6 million from $7.4 million. The filing reports a weighted-average interest rate on senior credit facilities of 3.24% for FY2022 versus 2.16% for FY2021; the year-end weighted-average rate was approximately 5.13%.
- Inventory increased to $168.0 million from $125.7 million, and operating cash flow declined year over year, mainly reflecting inventory investment and bonus payments. Capital expenditures were $19.6 million.
Debt and liquidity
- Year-end borrowings under senior credit facilities were $440.3 million in principal: $81.9 million term loan and $358.4 million revolving credit facility. Cash was $100.1 million, and unused revolving capacity was $336.6 million.
- The credit facility maturity was extended to March 2027; U.S. dollar borrowings transitioned from LIBOR to SOFR. The company reported compliance with covenants: leverage ratio 2.24 versus a maximum of 3.50, and fixed-charge coverage ratio 7.74 versus a minimum of 1.50.
- Management said operating cash flows and available borrowing capacity should meet operating and capital needs for at least the next 12 months. Estimated 2023 capital expenditures are $25–$30 million. Contractual purchase obligations were $145.0 million, of which $142.7 million was expected in 2023.
Changes, outlook and risks
- Precision Motion revenue grew 45.2%, including $88.0 million of contributions from 2021 acquisitions; microelectronics demand declined. Vision grew 6.1%, with supply-related production delays partly offsetting demand for minimally invasive surgery products.
- Backlog was $611.6 million at year-end, up from $568.8 million. Management cautioned that backlog is not a complete indicator of future revenue because customers may reschedule orders and supply or manufacturing capacity may fluctuate.
- Inflation drove higher materials, component and labor costs. Novanta generally offset increases through productivity actions and price increases but warned that recovery may lag or be limited by market conditions and competition. Supply constraints, transportation delays and China lockdowns affected operations.
- The company initiated a 2022 restructuring program, recorded $1.4 million of related costs, and expected another $4.0–$4.5 million of charges, with substantial completion anticipated in Q4 2023. It also expected $0.5–$1.0 million of additional costs to complete its 2020 restructuring program.
- No specific revenue or earnings guidance is provided in the supplied filing text. Other material risks include economic and end-market cyclicality, acquisition integration, reliance on some limited or single-source suppliers, foreign exchange and interest-rate exposure, medical-device regulation, cybersecurity, and execution of product development.
- FY2022 tax provision was $13.1 million, with a 15.0% effective tax rate versus 10.4% in FY2021. Required capitalization and amortization of R&D costs under the U.S. tax law reduced FY2022 operating cash flow by approximately $11.3 million, according to management.
Important facts for investors to verify
- Review the full-year versus standalone Q4 figures in the company’s quarterly filing; this 10-K text does not clearly state standalone Q4 results.
- Assess how much revenue growth and operating improvement came from acquisitions versus underlying demand, and whether Precision Motion’s acquisition-related growth and margins are sustainable.
- Track inventory, operating cash conversion and backlog conversion as supply constraints ease and customers adjust order lead times.
- Monitor variable-rate debt costs, covenant headroom, cash availability across jurisdictions, and the planned 2023 capital spending and restructuring costs.
- Confirm the status of supply-chain constraints, medical-device certification transitions, and other regulatory or legal contingencies. The filing says the prior arbitration matter was settled without damages and management did not expect other claims to have a material adverse effect.